Brief: IN8bio Announces Positive Updates From GBM Treatment Phase 1 Trial Presented At ASCO 2022

IN8bio

06/06/2022 12:28

June 6 (Reuters) - IN8BIO Inc  INAB.O :
    * IN8BIO ANNOUNCES POSITIVE GLIOBLASTOMA MULTIFORME (GBM)
CLINICAL
UPDATES FROM THE INB-200 PHASE 1 TRIAL PRESENTED AT ASCO 2022
    * IN8BIO, INC. - 100% OF DOSED PATIENTS HAVE EXCEEDED BOTH
MEDIAN
AND EXPECTED PROGRESSION FREE SURVIVAL
    * IN8BIO, INC. - TWO PATIENTS, TO DATE, HAVING EXCEEDED
THEIR
EXPECTED OVERALL SURVIVAL (OS).
    * IN8BIO, INC. - ALL PATIENTS DOSED DEMONSTRATING A
MANAGEABLE
SAFETY AND TOLERABILITY PROFILE

Source text for Eikon:  ID:nGNX2vZXWp 
Further company coverage:  INAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))